Science Translational Medicine
July 25, 2022
The Irvine Lab is developing an intranasal vaccine that can bypass multiple barriers in the nasal cavity and activate a frontline defense against mucosally-transmitted pathogens. Such immunization strategies are much needed across the infectious disease landscape but are limited by poor uptake across mucosal surfaces. In a cover story appearing in Science Translational Medicine, the researchers describe how they use the naturally-occurring protein albumin to chaperone vaccine components across the mucosal lining and into the nasal-associated lymphoid tissues where they can generate an effective immune response. The work is also featured in the 2022 Image Awards exhibition.